Biodesix

BDSX

Market cap $126M

The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.

LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate in two upcoming investor conferences:

LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc.  (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo.

The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.